

# Reagent Control in the Aldol Addition Reaction of Chiral Boron Enolates with Chiral $\alpha$ -Amino Aldehydes. Total Synthesis of (3*S*,4*S*)-Statine

Cesare Gennari,\* Gilles Pain, and Daniela Moresca

Dipartimento di Chimica Organica e Industriale,  
Universita' di Milano, Centro CNR (Sost. Org. Nat.), via G.  
Venezian 21, 20133 Milano, Italy

Received June 22, 1995

Over the past 10 years chiral  $\alpha$ -amino aldehydes have become very popular as synthetic precursors of biologically active molecules.<sup>1</sup> In this paper, we report on the stereoselective aldol reactions involving chiral *N,N*-diprotected  $\alpha$ -amino aldehydes and chiral boron enolates.<sup>2</sup> The aldol reaction between an acetate-derived enolate and a chiral aldehyde creates a new stereogenic center and two possible diastereoisomers (Scheme 1).

In recent years two distinct ways of stereochemical control have been used: substrate control, in which the intrinsic stereochemical preference of the  $\alpha$ -amino aldehyde **1** determines the stereochemical outcome of the reaction, and reagent control, in which it is the chiral enolate's stereochemical preference that governs the reaction stereochemistry.<sup>2,3</sup> When achiral lithium enolates or achiral enolsilanes were used, selectivities ranged from modest to good in favor of either the "Felkin-Anh" products (**2-anti**) or the "chelation" products (**2-syn**), depending on the nitrogen protecting groups ( $R^1$ ,  $R^2$ ) and on the Lewis acid promoters.<sup>1b,4–10</sup> Only two types of chiral enolates were reported to control the stereochemistry of the addition to  $\alpha$ -amino aldehydes **1** ( $R^1 = R^2 = \text{Bn}$ ), with selectivities ranging from fair ( $de = 60\text{--}92\%$ )<sup>11</sup> to good ( $de = 86.6\text{--}93\%$ ).<sup>4a,12,13</sup>

We have exploited transition state computer modeling to develop two new boron reagents (**3**,  $X = \text{Cl}$ ; **4**,  $X = \text{Br}$ ; Scheme 2) which allow the enantioselective synthesis of ketone-derived *anti* (74–88% ee;  $R = \text{Me}$ ;  $R^1 = \text{alkyl, aryl}$ )

(1) Reviews: (a) Jurczak, J.; Golebiowski, A. *Chem. Rev.* **1989**, *89*, 149–164. (b) Reetz, M. T. *Angew. Chem., Int. Ed. Engl.* **1991**, *30*, 1531–1546.

(2) (a) For reviews on the aldol reaction, see: *Comprehensive Organic Synthesis*; Trost, B. M., Fleming, I., Eds.; Pergamon Press: Oxford, 1991; Vol. 2 (Heathcock, C. H., Ed.). (b) Heathcock, C. H. Reference 2a, Chapter 1.5, pp 133–179; Chapter 1.6, pp 181–238. (c) Kim, M.; Williams, S. F.; Masamune, S. Reference 2a, Chapter 1.7, pp 239–275.

(3) Masamune, S.; Choy, W.; Peterson, J. S.; Sita, L. R. *Angew. Chem., Int. Ed. Engl.* **1985**, *24*, 1.

(4) (a) Reetz, M. T. *Pure Appl. Chem.* **1988**, *60*, 1607. (b) Reetz, M. T.; Drewes, M. W.; Schmitz, A. *Angew. Chem., Int. Ed. Engl.* **1987**, *26*, 1141.

(5) (a) Rich, D. H.; Sun, E. T. O.; Boparai, A. S. *J. Org. Chem.* **1978**, *43*, 3624. (b) Rich, D. H.; Sun, E. T. O.; Ulm, E. *J. Med. Chem.* **1980**, *23*, 27. (c) Rittle, K. E.; Homnick, C. F.; Ponticello, G. S.; Evans, B. E. *J. Org. Chem.* **1982**, *47*, 3016.

(6) Hanson, G. J.; Baran, J. S.; Lindberg, T. *Tetrahedron Lett.* **1986**, *27*, 3577.

(7) (a) Ohfuné, Y.; Nishio, H. *Tetrahedron Lett.* **1984**, *25*, 4133. (b) Li, W. R.; Han, S. Y.; Joullié, M. M. *Tetrahedron* **1993**, *49*, 785.

(8) Mikami, K.; Kaneko, M.; Loh, T.-P.; Terada, M.; Nakai, T. *Tetrahedron Lett.* **1990**, *31*, 3909.

(9) Reetz, M. T.; Fox, D. N. A. *Tetrahedron Lett.* **1993**, *34*, 1119.


(10) Takemoto, Y.; Matsumoto, T.; Ito, Y.; Terashima, S. *Tetrahedron Lett.* **1990**, *31*, 217.

(11) (a) Cooke, J. W. B.; Davies, S. G.; Naylor, A. *Tetrahedron* **1993**, *49*, 7955. (b) Beckett, R. P.; Davies, S. G.; Mortlock, A. A. *Tetrahedron: Asymmetry* **1992**, *3*, 123.


(12) Reetz, M. T.; Rivadeneira, E.; Niemeyer, C. *Tetrahedron Lett.* **1990**, *31*, 3863.

(13) Reetz, M. T.; Kunisch, F.; Heitmann, P. *Tetrahedron Lett.* **1986**, *27*, 4721.

Scheme 1




Scheme 2



and unsubstituted aldols (55–76% ee;  $R = \text{H}$ ;  $R^1 = \text{alkyl, aryl}$ )<sup>14a</sup> and thioester-derived *anti* ( $\geq 98\%$  ee;  $R = \text{Me}$ ,  $R^1 = \text{SBu}^t$ ) and unsubstituted aldols (87–97% ee;  $R = \text{H}$ ,  $R^1 = \text{SBu}^t$ ).<sup>14b</sup> We have also recently reported that boron enolates derived from **4** or *ent-4* ( $X = \text{Br}$ ) show a high degree of reagent control in reactions with chiral aldehydes.<sup>14c</sup>

Here we report the high efficiency of this reaction involving  $\alpha$ -amino aldehydes and its application to the

(14) (a) Gennari, C.; Hewkin, C. T.; Molinari, F.; Bernardi, A.; Comotti, A.; Goodman, J. M.; Paterson, I. *J. Org. Chem.* **1992**, *57*, 5173. (b) Gennari, C.; Moresca, D.; Vieth, S.; Vulpetti, A. *Angew. Chem., Int. Ed. Engl.* **1993**, *32*, 1618. (c) Gennari, C.; Moresca, D.; Vulpetti, A.; Pain, G. *Tetrahedron Lett.* **1994**, *35*, 4623.




**Table 1. Aldol Addition Reactions of Chiral Boron Enolates with Chiral  $\alpha$ -Amino Aldehydes**

Entry	R	L	Substrates	3,4- <i>anti</i>	3,4- <i>syn</i>	Products	Yield %
1	Bn	L*	5a	98.6	1.4	6a	75
2	Bn	L**	5a	3.2	96.8	7a	70
3	Me	L*	5b	98.5	1.5	6b	80
4	Me	L**	5b	3.7	96.3	7b	75
5	<i>s</i> -Bu	L*	5c	98.2	1.8	6c	75
6	<i>s</i> -Bu	L**	5c	4.6	95.4	7c	71
7	<i>i</i> -Pr	L*	5d	>100	<1 <sup>a</sup>	6d	80
8	<i>i</i> -Pr	L**	5d	3.5	96.5	7d	72
9	<i>t</i> -Bu	L*	5e	>100	<1 <sup>a</sup>	6e	78
10	<i>t</i> -Bu	L**	5e	2.5	97.5	7e	71

<sup>a</sup> Not detected in the crude reaction mixture.

total synthesis of (3*S*,4*S*)-statine **12**,<sup>5a,10,11a,15</sup> the main component of pepstatin, which is a specific inhibitor of aspartic proteases.<sup>15c,d</sup> *N,N*-Dibenzylamino aldehydes **5** were prepared from the corresponding natural  $\alpha$ -amino acids according to the procedure described by Reetz.<sup>4b</sup> With the chiral boron enolates of *tert*-butyl thioacetate derived from *ent*-4 we are able to overcome the inherent substrate preference for the Felkin-type product (3,4-*anti*) observed with achiral enolates. It is worth noting that in the "matched" cases the 3,4-*anti*:3,4-*syn* diastereomeric ratios are  $\geq 98.2:1.8$ , while in the "mismatched" cases the 3,4-*syn*:3,4-*anti* ratios are  $\geq 95.4:4.6$ . These results prove that it is possible to obtain either the 3,4-*anti* (**6**) or the 3,4-*syn* (**7**) adduct with very high diastereoselectivity just by changing the chiral boron ligand configuration [ $L^*$  derived from (-)-menthone,  $L^{**}$  derived from (+)-menthone] (Scheme 3, Table 1).

Although the aldol products are contaminated by small amounts of the unwanted diastereomer (0–4.6%), they can be easily purified by flash chromatography. The ratios of the mixtures **6/7** were determined by <sup>13</sup>C-NMR analysis of the crude reaction mixtures after having previously fully characterized each diastereomer. We have determined the relative and absolute configuration of the aldol products by chemical correlation in a couple of cases (see below). We have also determined by these chemical correlations that both **6**- and **7**-type compounds are enantiomerically pure and, therefore, that in the aldol



<sup>a</sup> Key: (a) 1 N NaOH in THF; (b) CH<sub>2</sub>N<sub>2</sub> in MeOH; (c) HCO<sub>2</sub>NH<sub>4</sub>, Pd-C, MeOH, reflux; (d) Ac<sub>2</sub>O/Py; (e) concd HCl, 80 °C, 3 h; (f) DOWEX 50X8-100 (acid form).

reaction the substrates do not suffer any erosion of configurational integrity. The 3,4-*syn* aldol adducts **7c** and **7e** have been correlated with the known lactams **9**<sup>16</sup> and **11**,<sup>15a</sup> respectively, the latter leading in two steps to the natural  $\beta$ -hydroxy  $\gamma$ -amino acid statine **12**. Aldol adducts **7c** and **7e** were saponified and esterified with diazomethane to give methyl esters **8** and **10** in good yield (75% and 80%, respectively). Debenzoylation of the -NBn<sub>2</sub> group was achieved using a procedure originally introduced for the deprotection of monobenzylamines (HCO<sub>2</sub>NH<sub>4</sub>, Pd-C, MeOH, reflux).<sup>17</sup> Under these reaction conditions the hydroxy amino ester intermediate undergoes cyclization, generating the  $\gamma$ -lactam, which is acetylated to give **9** (in the isoleucine series). Compound **9** is obtained in 85% overall yield from **8**. The  $[\alpha]_D$  values of lactams **9** and **11** are in good agreement with those reported in the literature.<sup>15a,16</sup> Although the ring opening of **11** under acidic conditions<sup>15e</sup> has been reported to fail,<sup>15b</sup> we have found that when concentrated hydrochloric acid at 80 °C is used lactam **11** is converted into statine hydrochloride in good yield. The salt was dissolved in water and loaded onto an ion exchange column to deliver the free amino acid statine **12** as a white solid (Scheme 4).

**Acknowledgment.** We thank the Commission of the European Union (HCM Network Grant: ERB CHR XCT 930141) for a research fellowship (to G.P.) and for financial support.

**Supporting Information Available:** Experimental procedures for all reaction products and complete spectral and analytical data for compounds **6a–e**, **7a–e**, and **8–12** (8 pages).

JO951133J

(15) (a) Klutchko, S.; O'Brien, P.; Hodges, J. C. *Synth. Commun.* **1989**, *19*, 2573. (b) Koot, W. J.; van Ginkel, R.; Kranenburg, M.; Hiemstra, H.; Louwrier, S.; Moolenaar, M. J.; Speckamp, N. W. *Tetrahedron Lett.* **1991**, *32*, 401. (c) Williams, R. M.; Colson, P. J.; Zhai, W. *Tetrahedron Lett.* **1994**, *35*, 9371 and references cited therein. (d) Lu, Y.; Miet, C.; Kunesch, N.; Poisson, J. E. *Tetrahedron: Asymmetry* **1993**, *4*, 893 and references cited therein. (e) Katsuki, T.; Yamaguchi, M. *Bull. Chem. Soc. Jpn.* **1976**, *49*, 3287.

(16) Rinehart, K. L.; Sakai, R.; Kishore, V.; Sullins, D. W.; Li, K. M. *J. Org. Chem.* **1992**, *57*, 3007.

(17) (a) Ram, S.; Spicer, L. D. *Synth. Commun.* **1987**, *17*, 415. (b) Adger, B. M.; O'Farrel, C.; Lewis, N. J.; Mitchell, M. B. *Synthesis* **1987**, 53.